Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 86.4%

Neg 86.4% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.